Joachim Bertram

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany.

Part of Bristol Myers Squibb Co., Juno Therapeutics GmbH is a German company that researches and develops cellular therapies. The company is based in Munich, Germany. The CEOs of the company are David Walter Pignolet, Lothar Germeroth. Juno Therapeutics was acquired by Juno Therapeutics, Inc., part of Bristol Myers Squibb Co. from March 07, 2018 on May 11, 2015 for $232.80 million.

Repairon GmbH engages in the development, manufacture, and commercialization of induced pluripotent stem cell based tissues for organ repair. It offers therapeutic products such as tissue patches and pouches for the treatment of patients with heart failure caused by ischemic and dilatative cardiomyopathies. The company was founded by Wolfram Zimmermann in 2004 and is headquartered in Goettingen, Germany.